8-K/AEarnings & ResultsOther EventsExhibits & Filings

Merck & Co., Inc. 8-K/A Report, Financial Results (Apr 22, 2005)

Filed April 22, 2005For Securities:MRK

Summary

This 8-K/A filing from Schering-Plough Corporation (MRK is likely a typo in the prompt, as the filing is for Schering-Plough) is an amendment to a previously filed 8-K. The primary purpose of this amendment is to correct a typographical error in Exhibit 99.1, which is the press release detailing the company's first-quarter 2005 financial results. The filing also provides supplemental financial data as Exhibit 99.2. Investors should note that this is an amendment for a minor correction, not a material event disclosure. The core financial information was released previously. The filing also includes a standard "Disclosure Notice for Forward Looking Statements" that outlines various risks and uncertainties the company faces, which are typical for pharmaceutical companies and include factors like patent expirations, competitive pressures, regulatory changes, manufacturing issues, and product development challenges.

Key Highlights

  • 1Amendment filed to correct a typographical error in the previously issued Q1 2005 earnings press release (Exhibit 99.1).
  • 2The filing formally furnishes the press release regarding Schering-Plough's first-quarter 2005 financial results as Exhibit 99.1.
  • 3Supplemental financial data for the first quarter of 2005 is provided as Exhibit 99.2.
  • 4Includes a comprehensive "Disclosure Notice for Forward Looking Statements" detailing numerous risks and uncertainties.
  • 5Key risk factors mentioned include competitive pressures, patent uncertainties, regulatory hurdles, manufacturing issues, and potential impact of major product performance.
  • 6The filing does not disclose any new material financial results or significant operational changes beyond the correction of the typo.

Frequently Asked Questions

This filing is an amendment to a previous 8-K filing primarily to correct a typographical error in the press release announcing Schering-Plough's first-quarter 2005 financial results (Exhibit 99.1).

No, this filing is an amendment that corrects a typo in the press release detailing Q1 2005 results. The actual financial results were reported in the initial 8-K filing and its accompanying press release.

The notice outlines a broad range of risks, including competition from other pharmaceutical companies and generic drugs, patent disputes, regulatory approval processes, manufacturing compliance issues, potential adverse outcomes from litigation, changes in healthcare legislation, and economic factors. It also specifically mentions the potential impact on sales from major products like CLARITIN, CLARINEX, and the Merck/Schering-Plough Cholesterol Partnership products (ZETIA and VYTORIN).

No, the filing is for Schering-Plough Corporation. The prompt incorrectly stated Merck & Co., Inc. (MRK) as the company filing, but the 8-K/A document clearly identifies Schering-Plough Corporation as the registrant.